CSCO and ASCO recommend PD-1 inhibitors with chemotherapy for recurrent nasopharyngeal carcinoma
- **The CSCO and ASCO joint guideline recommends platinum-based chemotherapy plus a programmed cell death protein 1 (PD-1) inhibitor as preferred first-line therapy for medically fit patients with recurrent or metastatic nasopharyngeal carcinoma.
- Evidence supports platinum-based chemotherapy combined with a PD-1 inhibitor as the preferred first-line treatment for appropriate patients.
- Chemotherapy alone may be offered when immunotherapy is unsuitable or declined by the patient.
- After achieving disease control, maintenance PD-1 inhibition should be continued for up to two years.
The publication
**The CSCO and ASCO joint guideline recommends platinum-based chemotherapy plus a programmed cell death protein 1 (PD-1) inhibitor as preferred first-line therapy for medically fit patients with recurrent or metastatic nasopharyngeal carcinoma. Maintenance PD-1 inhibition for up to two years is advised after disease control, while salvage surgery or re-irradiation is recommended for isolated locoregional recurrence.**
Who the findings apply to
The recommendations apply to patients with recurrent and/or metastatic nasopharyngeal carcinoma who are medically fit for systemic therapy.
Why this matters
This guideline synthesizes evidence from randomized trials, meta-analyses, and clinical experience to standardize treatment approaches for recurrent and metastatic nasopharyngeal carcinoma. It addresses first-line systemic therapy, maintenance strategies, locoregional consolidation, and salvage options based on efficacy, safety, and patient-centered outcomes.
What the study found
Evidence supports platinum-based chemotherapy combined with a PD-1 inhibitor as the preferred first-line treatment for appropriate patients. Chemotherapy alone may be offered when immunotherapy is unsuitable or declined by the patient.
After achieving disease control, maintenance PD-1 inhibition should be continued for up to two years. Selected responders to first-line chemotherapy may also receive oral maintenance chemotherapy or locoregional consolidation intensity-modulated radiotherapy.
For patients with isolated locoregional recurrence amenable to local therapy, salvage surgery and re-irradiation are recommended options. Subsequent-line treatments include chemotherapy, PD-1 inhibitors, and antibody-drug conjugates.
What the result does not establish
Treatment selection depends on prior therapy, disease extent, patient fitness, resource availability, local drug approvals, and patient preferences. Early supportive and specialist interdisciplinary palliative care should accompany active anticancer treatment for advanced, incurable disease where available.
Authors’ conclusion
“Treatment should be individualized according to disease setting, prior therapy, expected toxicities, availability, local drug approvals, and patient preferences. Early supportive and specialist interdisciplinary palliative care, where available, should accompany active anticancer treatment for advanced, incurable disease.Additional information is available at www.ascopubs.org/topics/asco-guidelines/head-neck-cancer.”
Study and sources
Treatment of Recurrent and/or Metastatic Nasopharyngeal Carcinoma: CSCO and ASCO Joint Guideline
Guidelines & recommendations · Journal of clinical oncology · 2026-11-10
Sources and limitations
- PubMed record PMID 43008245 (PubMed / NLM · 2026-11-19)
Related briefings
Follow ENCLAI News
Get new briefings in your news reader. No ENCLAI account needed.
The daily disease brief
One email a day: what changed in official disease reporting worldwide, with the source named for every number. Reported facts only — no forecasts and no interpretation.


